☰

Craig D. Fisher, Ph.D. - Publications

Affiliations: 
2008 Pharmacology & Toxicology University of Arizona, Tucson, AZ 
Area:
Toxicology, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 450-60. PMID 22112382 DOI: 10.1124/Dmd.111.041095  0.766
2011 Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 2395-402. PMID 21878559 DOI: 10.1124/Dmd.111.041012  0.782
2011 Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1954-60. PMID 21737566 DOI: 10.1124/Dmd.111.040592  0.782
2010 Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 2293-301. PMID 20805291 DOI: 10.1124/Dmd.110.035006  0.733
2009 Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 2087-94. PMID 19651758 DOI: 10.1124/Dmd.109.027466  0.816
2009 Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, Cherrington NJ. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. European Journal of Pharmacology. 613: 119-27. PMID 19358839 DOI: 10.1016/J.Ejphar.2009.04.002  0.823
2008 Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis Archives of Toxicology. 82: 959-964. PMID 18488193 DOI: 10.1007/S00204-008-0312-Z  0.803
2008 Merrell MD, Jackson JP, Augustine LM, Fisher CD, Slitt AL, Maher JM, Huang W, Moore DD, Zhang Y, Klaassen CD, Cherrington NJ. The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1716-21. PMID 18474683 DOI: 10.1124/Dmd.108.020867  0.785
2008 Augustine LM, Fisher CD, Lickteig AJ, Aleksunes LM, Slitt AL, Cherrington NJ. Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats. Journal of Biochemical and Molecular Toxicology. 22: 93-100. PMID 18418895 DOI: 10.1002/Jbt.20224  0.779
2007 Lickteig AJ, Fisher CD, Augustine LM, Cherrington NJ. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology. 21: 216-20. PMID 17721935 DOI: 10.1002/Jbt.20177  0.823
2007 Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, Cherrington NJ. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1970-8. PMID 17640958 DOI: 10.1124/Dmd.107.015107  0.833
2007 Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman-McKeeman LD, Cherrington NJ. Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 995-1000. PMID 17353348 DOI: 10.1124/Dmd.106.014340  0.655
2006 Slitt AL, Cherrington NJ, Fisher CD, Negishi M, Klaassen CD. Induction of genes for metabolism and transport by trans-stilbene oxide in livers of Sprague-Dawley and Wistar-Kyoto rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1190-7. PMID 16621935 DOI: 10.1124/Dmd.105.007542  0.76
2005 Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, Ching B, Contreras P, Diaz JL, Fisher CD, Fritz LC, Gladstone P, Groessl T, Gu X, Herrmann J, et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. Journal of Medicinal Chemistry. 48: 6779-82. PMID 16250635 DOI: 10.1021/jm050307e  0.322
2004 Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. The Journal of Pharmacology and Experimental Therapeutics. 309: 634-40. PMID 14742742 DOI: 10.1124/jpet.103.062034  0.362
Show low-probability matches.